B-cell lymphoma diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{B-cell lymphoma}} {{CMG}} ; {{AE}} {{Adnan Ezici}} ==Overview== ==Diagnostic Study of Choice== === Study of choice === B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas. *Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name=...")
 
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 3: Line 3:
{{CMG}} ; {{AE}} {{Adnan Ezici}}
{{CMG}} ; {{AE}} {{Adnan Ezici}}
==Overview==
==Overview==
 
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. Excisional [[lymph node biopsy]] is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.
==Diagnostic Study of Choice==
==Diagnostic Study of Choice==
=== Study of choice ===
=== Study of choice ===
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].  
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]].  
*Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>
*Excisional [[lymph node biopsy]] is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>
*Fine-needle aspiration or core-needle biopsy specimens are usually insufficien because they have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.
*[[Fine-needle aspiration]] or core-needle biopsy specimens are usually insufficient because these methods have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with immunohistochemistry to determine the subtype.
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with [[immunohistochemistry]] to determine the subtype.
===== Diagnostic results =====
===== Diagnostic results =====
*The following findings on performing pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>
*The following findings on pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref>
**Reed-Sternberg cells (RS)
**[[Reed-Sternberg cells]] (RS)
**Lymphocyte predominant cells (LP)
**Lymphocyte predominant cells (LP)
*The following findings on immunophenotypic analysis are confirmatory for the following types of non-Hodgkin's lypmhoma:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref>
*The following findings on immunophenotypic analysis are confirmatory for the following types of [[non-Hodgkin's lypmhoma]]:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref>
**
**MYC-IGH rearrangement detected by [[FISH]] in the presence of a [[BCL2]] negative germinal centres phenotype is definitive for diagnosis of [[Burkitt lymphoma]].
**A disrupted structure of [[follicle center]] by sheets of large cells which are positive for pan-B-cell antigens (e.g., [[CD20]], CD79a) is definitive for diagnosis of [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid30859597">{{cite journal |vauthors=Liu Y, Barta SK |title=Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment |journal=Am J Hematol |volume=94 |issue=5 |pages=604–616 |date=May 2019 |pmid=30859597 |doi=10.1002/ajh.25460 |url=}}</ref>
**A [[chromosomal translocation]] t(11:14) is definitive for diagnosis of [[mantle cell lymphoma]].<ref name="pmid28699667">{{cite journal |vauthors=Vose JM |title=Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |journal=Am J Hematol |volume=92 |issue=8 |pages=806–813 |date=August 2017 |pmid=28699667 |doi=10.1002/ajh.24797 |url=}}</ref>
 


==References==
==References==

Latest revision as of 16:50, 6 May 2022

B-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating B-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

B-cell lymphoma diagnostic study of choice On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of B-cell lymphoma diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on B-cell lymphoma diagnostic study of choice

CDC on B-cell lymphoma diagnostic study of choice

B-cell lymphoma diagnostic study of choice in the news

Blogs on B-cell lymphoma diagnostic study of choice

Directions to Hospitals Treating B-cell lymphoma

Risk calculators and risk factors for B-cell lymphoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]

Overview

B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas. Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.

Diagnostic Study of Choice

Study of choice

B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas.

  • Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.[1][2][3][4]
  • Fine-needle aspiration or core-needle biopsy specimens are usually insufficient because these methods have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.
  • Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with immunohistochemistry to determine the subtype.
Diagnostic results


References

  1. Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL (July 2020). "Hodgkin lymphoma". Nat Rev Dis Primers. 6 (1): 61. doi:10.1038/s41572-020-0189-6. PMID 32703953 Check |pmid= value (help).
  2. 2.0 2.1 . PMID 27466666. Missing or empty |title= (help)
  3. Jiang M, Bennani NN, Feldman AL (May 2017). "Lymphoma classification update: B-cell non-Hodgkin lymphomas". Expert Rev Hematol. 10 (5): 405–415. doi:10.1080/17474086.2017.1318053. PMID 28395545.
  4. 4.0 4.1 Kaseb H, Babiker HM. PMID 29763144. Missing or empty |title= (help)
  5. Sapkota S, Shaikh H. PMID 32644754 Check |pmid= value (help). Missing or empty |title= (help)
  6. Liu Y, Barta SK (May 2019). "Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment". Am J Hematol. 94 (5): 604–616. doi:10.1002/ajh.25460. PMID 30859597.
  7. Vose JM (August 2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". Am J Hematol. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667.